Breaking News Instant updates and real-time market news.

VNDA

Vanda Pharmaceuticals

$14.95

-0.15 (-0.99%)

, HKMPY

Hikma

$34.30

(0.00%)

12:03
04/13/18
04/13
12:03
04/13/18
12:03

Vanda wins appeal case over patent infringement for Fanapt

Vanda Pharmaceuticals (VNDA) announced that the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District Court for the District of Delaware's decision that West Ward Pharmaceuticals, a subsidiary of Hikma Pharmaceuticals (HKMPY), infringed Vanda's U.S. Patent number 8,586,610 for Fanapt. The '610 Patent is set to expire November 2, 2027.

VNDA

Vanda Pharmaceuticals

$14.95

-0.15 (-0.99%)

HKMPY

Hikma

$34.30

(0.00%)

  • 08

    May

VNDA Vanda Pharmaceuticals
$14.95

-0.15 (-0.99%)

09/14/17
PIPR
09/14/17
NO CHANGE
Target $26
PIPR
Overweight
Vanda price target raised to $26 from $23 at Piper Jaffray
Piper Jaffray analyst Charles Duncan raised his price target for Vanda Pharmaceuticals to $26 saying the company's Phase II results with tradipitant in chronic pruritus associated with atopic dermatitis were positive. While the primary endpoint of change in average itch score did not reach statistical significance due to an uncooperative control arm, issues with reporting and variability on this endpoint make that not a surprise, Duncan tells investors in a research note. He feels that the totality of data "clearly show" activity in an all-comers atopic derm sample. The analyst keeps an Overweight rating on Vanda.
10/30/17
OPCO
10/30/17
NO CHANGE
Target $26
OPCO
Outperform
Vanda price target raised to $26 from $21 at Oppenheimer
Oppenheimer analyst Derek Archila raised his price target for Vanda to $26 from $21 based on his more bullish Hetlioz forecasts. The analyst believes the recent pullback provides a nice entry point for investors as he expects base business growth to accelerate in the next 12-18 months. Archila reiterates an Outperform rating on the shares.
11/13/17
OPCO
11/13/17
NO CHANGE
Target $25
OPCO
Outperform
Vanda selloff overdone, says Oppenheimer at Oppenheimer
Oppenheimer analyst Derek Archila believes the selloff post Q3 earnings is overdone and that fear of slowing Hetlioz volumes/sales is overblown. While there were some certain impacts to Hetlioz growth during Q3, the analyst continues to look at the bigger picture for the drug, particularly among sighted Non-24 patients which we view as a big opportunity. Archila would be a buyer, and retains high conviction on Hetlioz sales acceleration over the next 12-18 months and expect further upside. He reiterates an Outperform rating on the shares, while lowering his price target on the shares to $25 from $26.
01/19/18
GHSC
01/19/18
INITIATION
Target $20
GHSC
Buy
Vanda initiated with a Buy at Seaport Global
Seaport Global analyst Corey David initiated Vanda with a Buy and $20 price target. David said the long-term cash-flows from Fanapt and Hetlioz alone should be able to justify the current valuation, and potential upside would come with success on tradipitant on either one of its two indications being studied in the clinic.
HKMPY Hikma
$34.30

(0.00%)

05/17/17
JEFF
05/17/17
DOWNGRADE
JEFF
Underperform
Hikma downgraded to Underperform from Buy at Jefferies
Price target lowered to 1,450p.
08/21/17
JEFF
08/21/17
UPGRADE
JEFF
Hold
Hikma upgraded to Hold from Underperform at Jefferies
Jefferies analyst James Vane-Tempest upgraded Hikma to Hold from Underperform, saying its fundamentals are now skewed more to the upside than the downside. However, he lowered his price target on Hikma to 1,045p from 1,390p.
08/21/17
GSCO
08/21/17
DOWNGRADE
GSCO
Neutral
Hikma downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Yulia Gerasimova downgraded Hikma to Neutral from Buy and removed Hikma from Goldman's Pan-Europe Buy List, citing Roxane integration issues, delayed generic Advair approval, ongoing U.S. generics pricing erosion, and multiple guidance downgrades from the company.
08/22/17
08/22/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Mylan (MYL) downgraded to Hold from Buy at Argus with analyst Jasper Hellweg citing the cut in 2017 guidance. He said Mylan may also have difficulty improving operations in the near-term due to unfavorable EpiPen regulatory developments, pricing pressures, and increased competition. 2. Brookfield (BIP) downgraded to Neutral from Outperform at Credit Suisse, with analyst Andrew Kuske saying he is exiting his long "tactical trade" given recent outperformance. 3. Global Medical REIT (GMRE) downgraded to Neutral from Buy at DA Davidson with analyst Barry Oxford saying that the stock "could be range bound for a period of time" following the departures of the REIT's CEO and CFO and due to "potential concerns regarding the dividend and acquisitions." 4. NxStage Medical (NXTM) downgraded to Market Perform from Outperform at Leerink, as analyst Danielle Antalffy said it is unlikely another bidder will top Fresenius Medical's (FMS) $30 per share offer for the company. 5. Hikma (HKMPY) downgraded to Neutral from Buy at Goldman Sachs, with analyst Yulia Gerasimova citing Roxane integration issues, delayed generic Advair approval, ongoing U.S. generics pricing erosion, and multiple guidance downgrades from the company. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

GS

Goldman Sachs

$228.68

2.38 (1.05%)

10:35
07/16/18
07/16
10:35
07/16/18
10:35
Periodicals
Goldman Sachs may announce new CEO tomorrow, CNBC reports »

David Solomon will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRO

Marathon Oil

$20.30

-1.18 (-5.49%)

10:34
07/16/18
07/16
10:34
07/16/18
10:34
Technical Analysis
Technical Take: Marathon Oil tumbles with peers »

Shares of oil exploration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

PFE

Pfizer

$37.40

-0.13 (-0.35%)

, ONCE

Spark Therapeutics

$81.60

-3.32 (-3.91%)

10:34
07/16/18
07/16
10:34
07/16/18
10:34
Hot Stocks
Pfizer initiates pivotal Phase 3 program for hemophilia B gene therapy »

Pfizer (PFE) and Spark…

PFE

Pfizer

$37.40

-0.13 (-0.35%)

ONCE

Spark Therapeutics

$81.60

-3.32 (-3.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 10

    Sep

PEGI

Pattern Energy

$17.52

0.43 (2.52%)

10:34
07/16/18
07/16
10:34
07/16/18
10:34
Hot Stocks
Pattern Energy rises as Ontario cancellation fears subside »

Shares of Pattern Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPC

Edgewell Personal Care

$51.01

-0.63 (-1.22%)

10:30
07/16/18
07/16
10:30
07/16/18
10:30
Options
Call buyer opens a notable new position in Edgewell Personal Care »

Call buyer opens a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:30
07/16/18
07/16
10:30
07/16/18
10:30
General news
Treasury Option Action: bullish positioning in the 10-year »

Treasury Option Action:…

ARNC

Arconic

$19.08

1.69 (9.72%)

, APO

Apollo Global

$35.82

-0.31 (-0.86%)

10:23
07/16/18
07/16
10:23
07/16/18
10:23
Recommendations
Arconic, Apollo Global analyst commentary  »

Arconic could be worth…

ARNC

Arconic

$19.08

1.69 (9.72%)

APO

Apollo Global

$35.82

-0.31 (-0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

MSFT

Microsoft

$105.56

0.14 (0.13%)

10:20
07/16/18
07/16
10:20
07/16/18
10:20
Options
Notable spread in Microsoft ahead of earnings »

Notable spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

  • 08

    Aug

  • 04

    Sep

10:20
07/16/18
07/16
10:20
07/16/18
10:20
General news
The 0.4% U.S. May business inventory rise »

The 0.4% U.S. May…

LPG

Dorian LPG

$7.95

0.03 (0.38%)

10:19
07/16/18
07/16
10:19
07/16/18
10:19
Hot Stocks
Dorian LPG confirms receipt of director nominations from BW LPG »

Dorian LPG confirmed that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
07/16/18
07/16
10:17
07/16/18
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
07/16/18
07/16
10:16
07/16/18
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
07/16/18
07/16
10:15
07/16/18
10:15
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

10:15
07/16/18
07/16
10:15
07/16/18
10:15
General news
Treasury Action: yields remained elevated »

Treasury Action: yields…

NFLX

Netflix

$399.49

3.57 (0.90%)

, PH

Parker-Hannifin

$157.79

-3.79 (-2.35%)

10:14
07/16/18
07/16
10:14
07/16/18
10:14
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

NFLX

Netflix

$399.49

3.57 (0.90%)

PH

Parker-Hannifin

$157.79

-3.79 (-2.35%)

ROK

Rockwell Automation

$168.02

-3.1 (-1.81%)

FDX

FedEx

$231.55

-2.2 (-0.94%)

HAS

Hasbro

$94.14

-2.365 (-2.45%)

XON

Intrexon

$14.90

-0.48 (-3.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 23

    Jul

  • 25

    Jul

  • 17

    Sep

  • 20

    Sep

  • 21

    Sep

NFLX

Netflix

$399.49

3.57 (0.90%)

, PH

Parker-Hannifin

$157.79

-3.79 (-2.35%)

10:14
07/16/18
07/16
10:14
07/16/18
10:14
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

NFLX

Netflix

$399.49

3.57 (0.90%)

PH

Parker-Hannifin

$157.79

-3.79 (-2.35%)

ROK

Rockwell Automation

$168.02

-3.1 (-1.81%)

FDX

FedEx

$231.55

-2.2 (-0.94%)

HAS

Hasbro

$94.14

-2.365 (-2.45%)

XON

Intrexon

$14.90

-0.48 (-3.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 23

    Jul

  • 25

    Jul

  • 17

    Sep

  • 20

    Sep

  • 21

    Sep

WFC

Wells Fargo

$56.39

1.04 (1.88%)

, VFC

VF Corp.

$87.64

2.8 (3.30%)

10:14
07/16/18
07/16
10:14
07/16/18
10:14
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

WFC

Wells Fargo

$56.39

1.04 (1.88%)

VFC

VF Corp.

$87.64

2.8 (3.30%)

UPS

UPS

$111.28

2.3 (2.11%)

ALV

Autoliv

$106.19

0.46 (0.44%)

SAR

Saratoga Investment

$24.31

-0.32 (-1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

  • 20

    Jul

  • 23

    Jul

  • 06

    Aug

  • 07

    Aug

  • 08

    Aug

  • 12

    Apr

  • 13

    Jul

  • 15

    Oct

BAC

Bank of America

$29.10

0.565 (1.98%)

10:14
07/16/18
07/16
10:14
07/16/18
10:14
Hot Stocks
Bank of America reports June default rate 2.66% vs. 2.98% last month »

Reports 30-plus day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

RDY

Dr. Reddy's

$30.40

-2.86 (-8.60%)

10:13
07/16/18
07/16
10:13
07/16/18
10:13
Technical Analysis
Technical Take: Dr. Reddy's falls after injunction against Suboxone generic »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOGO

Gogo

$3.86

-0.17 (-4.22%)

10:10
07/16/18
07/16
10:10
07/16/18
10:10
Recommendations
Gogo analyst commentary  »

Gogo transformation plan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOXA

21st Century Fox

$46.67

-0.885 (-1.86%)

10:10
07/16/18
07/16
10:10
07/16/18
10:10
Options
Repeat of bullish three-way spreads in 21st Century Fox »

Repeat of bullish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

10:10
07/16/18
07/16
10:10
07/16/18
10:10
General news
U.S. business inventories rose 04% in May, with sales up 1.4%, as forecast »

U.S. business inventories…

CNXN

Connection

$34.08

(0.00%)

10:03
07/16/18
07/16
10:03
07/16/18
10:03
Downgrade
Connection rating change  »

Connection downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$308.63

-10.17 (-3.19%)

10:01
07/16/18
07/16
10:01
07/16/18
10:01
Technical Analysis
Technical Take: Tesla has a small potential bearish pattern »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:01
07/16/18
07/16
10:01
07/16/18
10:01
General news
Business Inventories data reported »

May Business Inventories…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.